Update On New Commercial Models: ZS' View Of Charge Backs, Rebates And Flexibility
Executive Summary
Pharmaceutical companies have been downsizing their sales forces and implementing new commercial models for several years in response to wide-ranging market changes, driven by growing payer influence and a lack of compelling new drugs. The size of the U.S. pharma sales force peaked in the second quarter of 2006 at 106,000, and fell to 91,000 by year-end 2008. It is expected to decline even further to 70,000 to 80,000 by year-end 2009, according to ZS Associates, a sales and marketing consulting firm.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth